MYOMO Business Summary

Myomo, Inc. (MYO) is a commercial-stage medical robotics company specializing in myoelectric orthotics designed to restore function to individuals with upper-limb paralysis caused by stroke, spinal cord injury, and other neuromuscular disorders. The company generates revenue primarily through the sale of its flagship MyoPro product line, utilizing a diversified multi-channel model: the Direct Billing channel, which accounts for approximately 73% of revenue by billing insurance providers like Medicare Part B; the International segment, driven largely by the German market; and the rapidly expanding Orthotics and Prosthetics (O&P) channel. Myomo’s competitive landscape includes Lifeward (formerly ReWalk Robotics), Ekso Bionics, and Wandercraft. While competitors often focus on lower-limb gait training, Myomo maintains a distinct market position as a leader in wearable, non-invasive upper-limb robotics with FDA-registered Class II medical devices for both clinical and home use. Founded in 2004 as an MIT spin-out by Stephen Kelly, John McBean, Mira Sahney, and Kailas Narendran, Myomo is currently led by Chairman and CEO Paul R. Gudonis, a veteran executive with a background in scaling technology firms like AT&T and BBN. The executive team includes CFO David Henry, Chief Medical Officer Dr. Harry Kovelman, and Chief Commercial Officer Micah Mitchell, with Malcolm Bock serving as VP of Engineering and Product Strategy. The company is supported by a seasoned Board of Directors, including Lead Independent Director Thomas Kirk and Audit Chair Heather Getz. Notable institutional backing comes from Rosalind Advisors, BlackRock, and Vanguard, while Avenue Capital provides strategic financing through a multi-million dollar term loan facility to support the company’s path toward cash flow breakeven.